Table 1.

Markers of ovarian reserve in SLE

Study	Type of study	No. CYC-untreated (CYC−) patients with SLE	Measure of ovarian reserve AMH AFC OV			Results	Comments
Gasparin et al9	Case-control	40	√	–	–	Comparable AMH levels in SLE/CYC− and control groups.
Gao et al10	Case-control	40	√	–	–	AMH of SLE/CYC− group was significantly lower than in control group (p<0.001).	AMH was negatively correlated with disease activity (SLEDAI) (p=0.033). AMH concentration in SLE/CYC− group with normal menstruation was higher than SLE/CYC− group with abnormal menstruation (p<0.001).
Angley et al39	Cohort	68	√	–	–	SLE/CYC− women were 1.5–1.6 times more likely to have AMH levels <1.0 ng/mL (PR 1.62, 95% CI 0.93 to 2.82) and AMH levels below the 25th percentile as compared with women without SLE (PR 1.55 (95% CI 0.97 to 2.47)).
Lawrenz et al38	Cross-sectional	33	√	–	–	AMH of SLE/CYC− group was significantly lower than in control group (p<0.05).	There was no correlation between AMH and illness duration or disease activity (SLEDAI).
Ulug et al40	Cohort	20	–	√	√	AFC and OV of SLE/CYC− group were significantly lower than in control group (p<0.001, p=0.006, respectively).	Menstrual irregularities significantly higher in SLE/CYC− group than in control group.
Di Mario et al41	Cross-sectional	86	√	–	–	Comparable AMH levels in SLE and control groups.

AFC, antral follicle count; AMH, anti-Müllerian hormone; CYC, cyclophosphamide; OV, ovarian volume; SLEDAI, SLE Disease Activity Index.